Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study

OBJECTIVE: Exposing tumor antigens to the immune system is the key to ensuring the efficacy of immunotherapy. SBRT is the main way to reveal the specifical antigens of tumors which can enhance the immune response. We aimed to explore the clinical efficacy and safety of Toripalimab combined with Anlo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yongbiao, Hong, Hanyin, Fang, Wenzheng, Zhang, Xia, Luo, Huachun, Chen, Zhijian, Yu, Jianda, Fan, Weiqiang, Chi, Xiaobin, Peng, Yonghai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065408/
https://www.ncbi.nlm.nih.gov/pubmed/37007075
http://dx.doi.org/10.3389/fonc.2023.1113389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065408/
https://www.ncbi.nlm.nih.gov/pubmed/37007075
http://dx.doi.org/10.3389/fonc.2023.1113389

Ejemplares similares